Skip to search formSkip to main contentSkip to account menu

ruxolitinib 25 MG Oral Tablet

Known as: RUXOLITINIB 25MG TAB,ORAL, RUXOLITINIB 25MG TAB,ORAL [VA Product], ruxolitinib (as ruxolitinib phosphate) 25 MG Oral Tablet 
National Institutes of Health

Related topics

Related topics

2 relations
Oral Tabletruxolitinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Real-World-Daten zu Ruxolitinib bei PV
2018
2018
Studiendaten stützen Ruxolitinib-Einsatz
Patienten mit Polycythaemia vera (PV) und Therapieresistenz oder Unverträglichkeit gegen Hydroxyurea profitieren von Ruxolitinib. 
2018
2018
Protéinose alvéolaire et infection à Mycobacterium Abscessus chez une patiente allogreffée de cellules souches hématopoïétiques : rôle du ruxolitinib ?
2017
2017
Les inhibiteurs de la voie des Janus-kinases : un traitement prometteur de la dermatomyosite pour inhiber de la voie de l’interféron
2016
2016
The Pan Class-I PI3K Inhibitor Copanlisib Has Preclinical Activity in Mantle Cell Lymphoma, Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia As Single Agent and in Combination with Other…
Introduction. Copanlisib is a pan class-I PI3K inhibitor (i) with preferred activity towards PI3Kα and PI3Kδ that is currently in… 
2016
2016
Abstract B114: Innate immunity modulators to enhance oncolytic VSV-GP for the treatment of ovarian cancer
Oncolytic viruses (OV) that preferentially replicate in and kill tumor cells are promissing novel treatment option for advanced… 
2015
2015
Ruxolitinib nun Standard bei Myelofibrose
Die DGHO empfiehlt den JAK1/2-Inhibitor Ruxolitinib in ihrer Leitlinie zur symptomatischen Therapie der Myelofibrose als… 
2014
2014
Safety and Efficacy of Ruxolitinib Retreatment after Treatment Interruption in Patients Enrolled in an Open-Label, Multicenter, Expanded-Access Study in Myelofibrosis
BACKGROUND: Ruxolitinib is a potent JAK1/JAK2 inhibitor that has demonstrated durable reductions in splenomegaly and… 
2014
2014
Ruxolitinib Overcomes the Adverse Prognostic Effect of Anemia in Patients with Myelofibrosis (MF)
BACKGROUND: Ruxolitinib (RUX) is a potent JAK1/JAK2 inhibitor that has demonstrated rapid and durable reductions in splenomegaly… 
2012
2012
Neue Therapiestrategien für BCR/ABL-negative myeloproliferative Neoplasien
Zusammenfassung Mit der Identifizierung der JAK2V617F-Mutation bei der essentiellen Thrombozythämie (ET), der Polyzythämia vera… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)